Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 2/2013

01.02.2013 | Retinal Disorders

Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion

verfasst von: Hae Min Kang, Eun Jee Chung, Yong Min Kim, Hyoung Jun Koh

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

To evaluate the baseline spectral-domain optical coherence tomography (SD-OCT) characteristics of macular edema (ME) due to branch retinal vein occlusion (BRVO) for visual outcome after intravitreal bevacizumab injection.

Methods

Fifty-nine patients treated in one eye with intravitreal bevacizumab for ME due to BRVO were retrospectively reviewed. Stepwise multiple regression analysis was used to evaluate the relative contribution of several variables, including SD-OCT characteristics such as photoreceptor inner segment/outer segment (IS/OS) integrity and external limiting membrane (ELM status), baseline best-corrected visual acuity (BCVA), and baseline central retinal thickness (CRT) with final visual outcome.

Results

Thirty-one patients (52.5 %) had disrupted photoreceptor IS/OS integrity. The mean BCVA improved significantly from 0.50 logMAR (20/63 Snellen equivalent) to 0.10 logMAR (20/25 Snellen equivalent) in the intact photoreceptor group (p = 0.000, paired t-test). However, the mean BCVA was improved in the disrupted photoreceptor group, from 1.10 logMAR (20/252 Snellen equivalent) to 0.94 logMAR (20/174 Snellen equivalent), which was not statistically significant (p = 0.177, paired t-test). ELM was disrupted in 23 patients (39.0 %). The mean BCVA improved significantly from 0.63 logMAR (20/85 Snellen equivalent) to 0.26 logMAR (20/36 Snellen equivalent) in the intact ELM group (p =  0.000, paired t-test), however, not significantly improved in the disrupted ELM group, from 1.09 logMAR (20/246 Snellen equivalent) to 1.01 logMAR (20/205 Snellen equivalent) (p =  0.563, paired t-test). The strongest individual predictor of final BCVA among patients with ME due to BRVO was the integrity of photoreceptor IS/OS layer on SD OCT (r 2 = 0.514, p = 0.000, stepwise multiple regression), but the most efficient model was the combination of the photoreceptor IS/OS integrity, ELM status, and baseline BCVA (r 2 = 0.671, p = 0.000, stepwise multiple regression). The strongest predictor of final BCVA was the status of photoreceptor IS/OS integrity (β = 0.532, p = 0.000, stepwise multiple regression), followed by ELM status (β = 0.325, p = 0.006, stepwise multiple regression), and the baseline BCVA (β = 0.238, p = 0.013, stepwise multiple regression).

Conclusion

Our results suggest that baseline SD-OCT characteristics, the status of photoreceptor IS/OS and ELM can be helpful in predicting the final visual outcome after intravitreal bevacizumab injection in these patients.
Literatur
1.
Zurück zum Zitat Greer DV, Constable IJ, Cooper RL (1980) Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol 8:207–209PubMedCrossRef Greer DV, Constable IJ, Cooper RL (1980) Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol 8:207–209PubMedCrossRef
2.
Zurück zum Zitat Rehak J, Rehak M (2008) Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 33:111–131PubMedCrossRef Rehak J, Rehak M (2008) Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 33:111–131PubMedCrossRef
3.
Zurück zum Zitat Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion; the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98:133–141PubMed Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion; the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98:133–141PubMed
4.
Zurück zum Zitat Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU (2007) Intravitreal bevacizumab (Avastin) for central and hemiretinal vein occlusions: IBeVO study. Retina 27:141–149PubMedCrossRef Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU (2007) Intravitreal bevacizumab (Avastin) for central and hemiretinal vein occlusions: IBeVO study. Retina 27:141–149PubMedCrossRef
5.
Zurück zum Zitat Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606PubMedCrossRef Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606PubMedCrossRef
6.
Zurück zum Zitat Kondo M, Kondo N, Ito Y, Kachi S, Kikuchi M, Yasuma TR, Ota I, Kensaku M, Terasaki H (2009) Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina 29:1242–1248PubMedCrossRef Kondo M, Kondo N, Ito Y, Kachi S, Kikuchi M, Yasuma TR, Ota I, Kensaku M, Terasaki H (2009) Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina 29:1242–1248PubMedCrossRef
7.
Zurück zum Zitat Badala F (2008) The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol 19:234–238PubMedCrossRef Badala F (2008) The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol 19:234–238PubMedCrossRef
8.
Zurück zum Zitat Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, Schmidt-Erfurth U (2009) Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 93:452–456PubMedCrossRef Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, Schmidt-Erfurth U (2009) Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 93:452–456PubMedCrossRef
9.
Zurück zum Zitat Hoeh AE, Ruppenstine M, Ach T, Ach T, Dithmar S (2010) OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 248:1567–1572PubMedCrossRef Hoeh AE, Ruppenstine M, Ach T, Ach T, Dithmar S (2010) OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 248:1567–1572PubMedCrossRef
10.
Zurück zum Zitat Holladay JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13:388–391PubMed Holladay JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13:388–391PubMed
11.
Zurück zum Zitat Hoh AE, Schaal KB, Dithmar S (2007) Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria, and Switzerland. Ophthalmologe 104:290–294PubMedCrossRef Hoh AE, Schaal KB, Dithmar S (2007) Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria, and Switzerland. Ophthalmologe 104:290–294PubMedCrossRef
12.
Zurück zum Zitat The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271–282 The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271–282
13.
Zurück zum Zitat Jonas JB, Akkoyun I, Kamppeer B, Kreissiq I, Degenring RF (1995) Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 19:65–71CrossRef Jonas JB, Akkoyun I, Kamppeer B, Kreissiq I, Degenring RF (1995) Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 19:65–71CrossRef
14.
Zurück zum Zitat Avitabile T, Longo A, Reibaldi A (2005) Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 140:695–702PubMedCrossRef Avitabile T, Longo A, Reibaldi A (2005) Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 140:695–702PubMedCrossRef
15.
Zurück zum Zitat Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S (2009) Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247:1635–1641PubMedCrossRef Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S (2009) Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247:1635–1641PubMedCrossRef
16.
Zurück zum Zitat Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ (2008) Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246:1241–1247PubMedCrossRef Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ (2008) Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246:1241–1247PubMedCrossRef
17.
Zurück zum Zitat Ach T, Hoeh AE, Schaal KB, Scheuerle AF, Dithmar S (2010) Predictive factors in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 248:155–159PubMedCrossRef Ach T, Hoeh AE, Schaal KB, Scheuerle AF, Dithmar S (2010) Predictive factors in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 248:155–159PubMedCrossRef
18.
Zurück zum Zitat Ota M, Tsujikawa A, Murakami T, Yamaike N, Sakamoto A, Kotera Y, Miyamoto K, Kita M, Yoshimura N (2008) Foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 145:273–280PubMedCrossRef Ota M, Tsujikawa A, Murakami T, Yamaike N, Sakamoto A, Kotera Y, Miyamoto K, Kita M, Yoshimura N (2008) Foveal photoreceptor layer in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 145:273–280PubMedCrossRef
19.
Zurück zum Zitat Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92:518–522PubMedCrossRef Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92:518–522PubMedCrossRef
20.
Zurück zum Zitat Spaide RF, Lee JK, Klancnik JM, Gross NE (2003) Optical coherence tomography of branch retinal vein occlusion. Retina 23:343–347PubMedCrossRef Spaide RF, Lee JK, Klancnik JM, Gross NE (2003) Optical coherence tomography of branch retinal vein occlusion. Retina 23:343–347PubMedCrossRef
21.
Zurück zum Zitat Yamaike N, Tsujikawa A, Ota M, Sakamoto A, Kotera Y, Kita M, Miyamoto K, Yoshimura N, Hangai M (2008) Three-dimensional imaging of cystoid macular edema in retinal vein occlusion. Ophthalmology 115:355–362PubMedCrossRef Yamaike N, Tsujikawa A, Ota M, Sakamoto A, Kotera Y, Kita M, Miyamoto K, Yoshimura N, Hangai M (2008) Three-dimensional imaging of cystoid macular edema in retinal vein occlusion. Ophthalmology 115:355–362PubMedCrossRef
22.
Zurück zum Zitat Murakami T, Tsujikawa A, Ohta M, Miyamoto K, Kita M, Watanabe D, Takagi H, Yoshimura N (2007) Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator. Am J Ophthalmol 143:171–173PubMedCrossRef Murakami T, Tsujikawa A, Ohta M, Miyamoto K, Kita M, Watanabe D, Takagi H, Yoshimura N (2007) Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator. Am J Ophthalmol 143:171–173PubMedCrossRef
23.
Zurück zum Zitat Eandi CM, Chung JE, Cardillo-Piccolino F, Spaide RF (2005) Optical coherence tomography in unilateral resolved central serous chorioretinopathy. Retina 25:417–421PubMedCrossRef Eandi CM, Chung JE, Cardillo-Piccolino F, Spaide RF (2005) Optical coherence tomography in unilateral resolved central serous chorioretinopathy. Retina 25:417–421PubMedCrossRef
24.
Zurück zum Zitat Piccolino FC, de la Longrais RR, Ravera G, Eandi CM, Ventre L, Abdollahi A, Manea M (2005) The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol 139:87–99PubMedCrossRef Piccolino FC, de la Longrais RR, Ravera G, Eandi CM, Ventre L, Abdollahi A, Manea M (2005) The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol 139:87–99PubMedCrossRef
25.
Zurück zum Zitat Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL (2005) The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci 46:3349–3354PubMedCrossRef Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL (2005) The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci 46:3349–3354PubMedCrossRef
26.
Zurück zum Zitat Maheshwary AS, Oster SF, Yuson RM, Cheng L, Mojana F, Freeman WR (2010) The association between percent disruption of the photoreceptor inner segment–outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol 150:63–67PubMedCrossRef Maheshwary AS, Oster SF, Yuson RM, Cheng L, Mojana F, Freeman WR (2010) The association between percent disruption of the photoreceptor inner segment–outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol 150:63–67PubMedCrossRef
27.
Zurück zum Zitat Shin HJ, Chung H, Kim HC (2011) Association between integrity of foveal photoreceptor layer and visual outcome in retinal vein occlusion. Acta Ophthalmol 89:35–40CrossRef Shin HJ, Chung H, Kim HC (2011) Association between integrity of foveal photoreceptor layer and visual outcome in retinal vein occlusion. Acta Ophthalmol 89:35–40CrossRef
28.
Zurück zum Zitat Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C, Diabetic Retinopathy Research Group Vienna (2009) Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 116:914–920PubMedCrossRef Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C, Diabetic Retinopathy Research Group Vienna (2009) Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 116:914–920PubMedCrossRef
29.
Zurück zum Zitat Ota M, Nishijima K, Sakamoto A, Murakami T, Takayama K, Horii T, Yoshimura N (2010) Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment. Ophthalmology 117:1996–2002PubMedCrossRef Ota M, Nishijima K, Sakamoto A, Murakami T, Takayama K, Horii T, Yoshimura N (2010) Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment. Ophthalmology 117:1996–2002PubMedCrossRef
30.
Zurück zum Zitat Wolf-Schnurrbusch UE, Ghanem R, Rothenbuehler SP, Enzmann V, Framme C, Wolf S (2011) Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion. Invest Ophthalmol Vis Sci 52:3334–3337PubMedCrossRef Wolf-Schnurrbusch UE, Ghanem R, Rothenbuehler SP, Enzmann V, Framme C, Wolf S (2011) Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion. Invest Ophthalmol Vis Sci 52:3334–3337PubMedCrossRef
31.
Zurück zum Zitat Ota M, Tsujikawa A, Murakami T, Kita M, Miyamoto K, Sakamoto A, Yamaike N, Yoshimura N (2007) Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol 91:1644–1649PubMedCrossRef Ota M, Tsujikawa A, Murakami T, Kita M, Miyamoto K, Sakamoto A, Yamaike N, Yoshimura N (2007) Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol 91:1644–1649PubMedCrossRef
Metadaten
Titel
Spectral-domain optical coherence tomography (SD-OCT) patterns and response to intravitreal bevacizumab therapy in macular edema associated with branch retinal vein occlusion
verfasst von
Hae Min Kang
Eun Jee Chung
Yong Min Kim
Hyoung Jun Koh
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 2/2013
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-012-2067-8

Weitere Artikel der Ausgabe 2/2013

Graefe's Archive for Clinical and Experimental Ophthalmology 2/2013 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.